Daily Respiratory Research Analysis
Three impactful respiratory papers span clinical, mechanistic, and systems biology advances: a multicentre prospective cohort shows positive airway pressure therapy lowers long-term cardiovascular events and mortality in obstructive sleep apnoea; a mechanistic Blood study identifies recipient TLR9 sensing of mitochondrial DNA as a priming “first hit” for TRALI with blockade by a TLR9 antagonist; and a National Science Review multi-omics analysis delineates shared and subgroup-specific pathways a
Summary
Three impactful respiratory papers span clinical, mechanistic, and systems biology advances: a multicentre prospective cohort shows positive airway pressure therapy lowers long-term cardiovascular events and mortality in obstructive sleep apnoea; a mechanistic Blood study identifies recipient TLR9 sensing of mitochondrial DNA as a priming “first hit” for TRALI with blockade by a TLR9 antagonist; and a National Science Review multi-omics analysis delineates shared and subgroup-specific pathways and biomarkers in long COVID.
Research Themes
- OSA therapy reduces cardiovascular risk and mortality
- Innate immune sensing (TLR9–mtDNA) primes TRALI
- Long COVID heterogeneity mapped by multi-omics with candidate biomarkers
Selected Articles
1. Major cardiovascular event or death risk in obstructive sleep apnoea and the effect of positive airway pressure.
In a multicentre prospective cohort of 5,358 OSA patients followed a median 14 years, positive airway pressure (PAP) therapy was associated with reduced risks of non-fatal major cardiovascular events and all-cause mortality. The authors also derived and validated a risk estimator incorporating PAP adherence with clinical and sleep metrics to guide therapy decisions.
Impact: This study links PAP adherence to long-term cardiovascular and survival benefits and provides a practical, validated risk estimator, addressing a major gap in OSA outcomes evidence.
Clinical Implications: Reinforce PAP adherence and use a validated risk estimator to identify high-risk OSA patients most likely to benefit, integrating cardiovascular risk reduction into sleep medicine practice.
Key Findings
- PAP therapy was associated with long-term reductions in non-fatal major cardiovascular events and all-cause mortality in OSA.
- A risk estimator incorporating PAP adherence plus clinical and sleep-related variables was derived and validated.
- Large prospective cohort with median 14-year follow-up strengthens prognostic inference for OSA management.
Methodological Strengths
- Multicentre prospective cohort with large sample size and long follow-up
- Derivation and validation of a predictive risk estimator including treatment adherence
Limitations
- Observational design limits causal inference and may retain residual confounding
- Effect sizes and subgroup performance are not fully detailed in the abstract
Future Directions: Prospective implementation and external-validation studies across diverse populations; randomized or quasi-experimental designs to test PAP’s cardiovascular benefits; integration of the risk estimator into clinical workflows.
BACKGROUND: Evidence regarding the efficacy of positive airway pressure (PAP) therapy in reducing the risk of non-fatal major cardiovascular events (NF-MACE) and mortality in patients with obstructive sleep apnoea (OSA) remains controversial. This study aims to quantify the impact of PAP therapy on these risks and develop a predictive risk estimator. METHODS: We conducted a multicentre, observational, prospective study involving 5358 individuals diagnosed with OSA, with a median (interquartile range (IQR)) follow-up of 14 (10-15) years. We derived and validated a risk estimator of NF-MACE (including myocardial infarction, stroke, revascularisation procedures and congestive heart failure) and all-cause mortality, incorporating PAP adherence alongside clinical and sleep-related data. RESULTS: The cohort had mean±sd age 55±11 years, body mass index 32.0±5.4 kg·m CONCLUSIONS: PAP therapy is associated with long-term risk reduction of NF-MACE and mortality in OSA patients, while the developed risk estimator enhances clinical decision making regarding therapy initiation.
2. Mitochondrial DNA via recipient TLR9 acts as a potent first hit in murine transfusion-related acute lung injury.
In a murine two-hit model of TRALI, mitochondrial DAMPs—especially mtDNA—prime severe lung injury via recipient TLR9 signaling. A TLR9 antagonist abrogated mtDAMP-induced TRALI, whereas FPR antagonists did not, pinpointing mtDNA–TLR9 as a mechanistic first-hit axis.
Impact: This is a rigorous mechanistic dissection identifying mtDNA–TLR9 signaling as a tractable target for TRALI prevention, with direct translational implications for blood storage, patient risk stratification, and therapeutic development.
Clinical Implications: Consider strategies to reduce mtDNA burden in transfusion products and explore recipient-directed TLR9 inhibition in high-risk settings (e.g., trauma, inflammatory states) to mitigate TRALI risk.
Key Findings
- Purified mitochondria plus anti-MHC I antibody produced exaggerated lung injury with edema, elevated MIP-2, neutrophil influx, hypothermia, and respiratory distress.
- TLR9 agonist or purified mtDNA recapitulated priming; a TLR9 antagonist blocked mtDAMP-induced TRALI, while two FPR antagonists did not.
- Findings implicate mtDNA–TLR9 signaling as a priming ‘first hit’ from transfusion products and recipient plasma.
Methodological Strengths
- In vivo mechanistic model with multiple convergent agonists and antagonists to test causality
- Comprehensive phenotyping of lung injury (edema, cytokines, neutrophils, physiologic distress)
Limitations
- Animal model; translational relevance to human TRALI requires clinical validation
- Dose–response thresholds of mtDNA in human blood products were not defined
Future Directions: Quantify mtDNA in blood components and recipients; test TLR9 antagonists in translational models and early-phase clinical trials; optimize blood processing to reduce mtDAMP load.
Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-related mortality. Though the precise mechanism is not fully understood, a 2-hit model is widely accepted, involving both a predisposing patient condition and the transfusion itself. Mitochondrial damage-associated molecular patterns (mtDAMPs), such as mitochondrial DNA (mtDNA) and N-formylated peptides (NFPs), are elevated in patients who have experienced trauma, and stored blood products, and have been implicated in adverse transfusion outcomes, prompting us to investigate whether mtDAMPs could serve as a priming "first hit" in TRALI. Using a murine model, we found that injection of purified mitochondria followed by a monoclonal anti-major histocompatibility complex class I antibody (34-1-2s) induced significantly greater lung injury compared with the isotype control. This was evidenced by increased pulmonary edema, elevated plasma macrophage inflammatory protein 2, enhanced neutrophil lung infiltration, hypothermia, and respiratory distress. Similar effects were observed using a Toll-like receptor 9 (TLR9) agonist (oligonucleotide 2395), purified mtDNA, and a synthetic NFP (WKYMVm), agonist of formyl peptide receptor (FPR). Notably, a TLR9 antagonist blocked the mtDAMP-induced TRALI response, whereas 2 FPR antagonists did not, underscoring a key role for mtDNA and TLR9 signaling in disease priming. These findings suggest that mtDAMPs, particularly mtDNA, present in both transfusion products and recipient plasma, may predispose patients to antibody-mediated TRALI. Targeting mtDAMPs or their receptors may offer a novel therapeutic strategy to mitigate TRALI risk.
3. Integrated multi-omics characterization across clinically relevant subgroups of long COVID.
Integrated transcriptomic, proteomic, and metabolomic profiling revealed elevated MAPK activity in long COVID and down-regulation in recovered individuals. Distinct subgroup-specific metabolic and immune signatures and both general (ABHD17A, CSNK1D, PSME4, SYVN1) and serum subgroup biomarkers (CRH, FPGT, CBX6, RBBP4) were identified.
Impact: This work defines shared and divergent pathophysiology across clinically relevant long COVID subtypes and nominates actionable biomarkers, laying groundwork for stratified diagnostics and targeted interventions.
Clinical Implications: Supports development of biomarker panels for diagnosis and patient stratification in long COVID and informs hypothesis-driven, subgroup-tailored therapeutic trials.
Key Findings
- Long COVID showed global MAPK pathway activation, whereas recovered individuals showed down-regulation.
- Each clinical subgroup had distinct multi-omics signatures (e.g., CAPM with inhibited NF-κB; MULTI and MSK+SYST with elevated glycerophospholipid metabolism).
- General biomarkers (ABHD17A, CSNK1D, PSME4, SYVN1) and subgroup-specific serum proteins (CRH, FPGT, CBX6, RBBP4) were identified.
Methodological Strengths
- Integrated multi-omics (transcriptome, proteome, metabolome) across clinically defined subgroups
- Convergent pathway-level analyses linking molecular signatures to symptom clusters
Limitations
- Sample size and cohort composition not detailed in the abstract; external validation is needed
- Cross-sectional nature limits causal inference and temporal dynamics
Future Directions: Prospective validation of biomarker panels, development of clinically deployable assays, and subgroup-tailored interventional trials guided by the identified pathways.
When SARS-CoV-2 became regional epidemics, a substantial number of patients suffered from post-acute sequelae of COVID-19 (PASC, aka long COVID). Exploring the pathogenesis and especially the heterogenicity features of long COVID subgroups is of paramount importance for understanding its etiology. In this study, through integrative multi-omics analyses encompassing transcriptomics, proteomics, and metabolomics, long COVID patients exhibited overall elevated MAPK pathway activation, while patients who have recovered from long COVID showed down-regulation of this response. Long COVID heterogenicity is described by multi-omics distinct signatures for each subgroup. The Multisystemic (MULTI) symptom subgroup is characterized by enhanced glycerophospholipid and ether lipid metabolism, Neurological (NEU) by augmented glycoprotein synthesis metabolism, Cardio cerebral (CACRB) by increased pyruvate metabolism and suppressed macrophage polarization, Musculoskeletal + Systemic (MSK + SYST) by elevated glycerophospholipid metabolism, and Cardiopulmonary (CAPM) by inhibited NF-κB signaling pathways. ABHD17A, CSNK1D, PSME4 and SYVN1 were general long COVID combination biomarkers, while CRH (MULTI), FPGT (NEU), CBX6 (CACRB) and RBBP4 (CAPM) were selected as serum-specific subgroup proteins. Our study provides a commonly shared and distinct pathophysiological explanation underpinning PASC, paving the way for future diagnosis and therapeutic interventions.